Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
recombinant H7 hemagglutinin influenza vaccine + Advax-2
- Development stage
- Unknown
- Lead developer
- Vaxine
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Recombinant H7 hemagglutinin influenza vaccine + Advax-2 is an investigational adjuvanted subunit vaccine designed to protect against H7N9 avian influenza. The vaccine consists of a recombinant H7 hemagglutinin (HA) protein, typically derived from the A/Anhui/1/2013 (H7N9) strain and produced in an insect cell/baculovirus expression system, combined with the Advax-2 adjuvant. Advax-2 is a proprietary adjuvant platform developed by Vaxine Pty Ltd, comprising delta-inulin (a plant-derived polysaccharide) and a synthetic Toll-like receptor 9 (TLR9) agonist (CpG oligonucleotide). This combination is intended to enhance the magnitude and breadth of the immune response, particularly in pandemic scenarios where H7N9 poses a significant zoonotic threat. Clinical studies have evaluated its safety and immunogenicity, demonstrating the ability of Advax-2 to significantly boost antibody titers and cellular immunity compared to unadjuvanted recombinant HA.
- Other names
- rH7HA + Advax-2H7N9 vaccine + Advax-2recombinant H7 hemagglutinin influenza vaccine + Advax-2 adjuvant
02
Targets
TLR9 (Toll-like receptor 9)
Beyond the preview
Go deeper on recombinant H7 hemagglutinin influenza vaccine + Advax-2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on recombinant H7 hemagglutinin influenza vaccine + Advax-2.